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Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at the 
time of publication and may evolve as the science develops. 
INTRODUCTION
The novel coronavirus outbreak, which began as an epidemic 
in Wuhan, China, in December 2019 has been confirmed to 
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In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. 
To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 
million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for 
COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an 
effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous 
(IV) remdesivir was performed. Remdesivir, an anti-viral prodrug originally developed to treat Ebola 
virus disease, has shown broad spectrum activity against the Coronavirus family. A recent case report 
reported improvement of clinical symptoms with remdesivir in a patient with COVID-19. After conducting 
a systematic search of 18 clinical trial registries and three large scientific databases, we identified 
86 potentially eligible items. Following removal of duplicates (n = 21), eligible studies were reviewed 
independently by two authors. After the first round of screening, inter-rater agreement was 98.5% (κ = 
0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven 
ongoing and recruiting clinical trials of remdesivir (100-200 milligrams, intravenous [IV]) were included. We 
identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement 
(n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 
1). Secondary outcomes in all identified studies included documentation of adverse events. Phase 3 trials 
are expected to be completed between April 2020–2023. Therefore, despite supportive data from in vitro 
and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side 
effects remain incompletely defined in the human population. [West J Emerg Med. 2020;21(4)X–X.]
share 79.6% sequence identity with SARS-CoV and 96% 
genome identity with a coronavirus species in bats, its natural 
reservoir.1 Initially referred to as 2019-nCoV, the virus has been 
renamed SARS-CoV-2, and the disease that results is coronavirus 
disease-2019 (COVID-19).2 At the time of this authorship, there 
are over 1.6 million confirmed cases and over 99,000 deaths 
in 205 countries worldwide.3 On March 11, 2020, the World 
Health Organization responded to the unprecedented spread 
of COVID-19 and inaction of international governments by 
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declaring the outbreak a pandemic.4
There is currently no safe and proven treatment for 
COVID-19 and there is no vaccine for SARS-CoV-2; however, 
vaccines are under development and several treatments have been 
proposed and are under investigation.5-6 The rapid international 
spread and severity of COVID-19, which causes symptoms 
varying from fever, dry cough, and shortness of breath to diarrhea 
and body aches, has spurred the greater scientific community 
to quickly identify treatments for the disease.4 Potential 
pharmacological treatments for COVID-19 may be found in one 
of three categories: broad-spectrum anti-viral drugs; repurposed 
existing drugs or substances; and novel therapeutic agents.7 We 
chose to analyze remdesivir based on established inhibition of 
infection by the novel coronavirus in human cell lines (human 
liver cancer HuH-7 cells).8
Remdesivir falls into the first category as an anti-viral 
prodrug developed to treat infections caused by viruses of 
the family Filoviridae, which includes Ebola virus (Zaire 
embolavirus).9 Discovered in 2016 small molecule GS-5734, 
remdesivir was used initially to treat Ebola virus disease (EVD) as 
an adenosine analog that incorporates into viral RNA, leading to 
premature chain termination and inhibition of viral replication.10 
But in 2019, the first confirmed case of COVID-19 in the 
United States prompted the use of intravenous (IV) remdesivir 
for compassionate use, leading to marked improvement of the 
patient’s clinical status within 24 hours.11 The authors suggested 
that additional clinical studies were needed to complete the safety 
and efficacy profiles of the anti-viral drug. Given the worldwide 
urgency for an effective and safe treatment for COVID-19 and 
the therapeutic potential of remdesivir, this systematic review 
was performed to determine the outcomes and adverse events 
associated with this investigational, anti-viral medication. 
METHODS
We performed a systematic review of the use of remdesivir 
for treatment of COVID-19. Eligibile articles included human 
patients with SARS-CoV-2 infection, remdesivir administration, 
patient outcomes, and adverse events. A search strategy was 
developed for each database without restrictions for language 
or years considered. The search parameters for Embase were as 
follows: 
(1) remdesivir OR GS-5734
(2) coronavirus OR coronaviruses OR 2019-nCoV OR 
COVID-19 OR SARS-CoV-2 OR SARS-COV2
(3)  #1 AND #2
Clinical trial registries that were searched included the 
following: clinicaltrials.gov; Chinese Clinical Trial Registry 
(ChiCTR); Australian New Zealand Trial Registry; Brazilian 
Clinical Trials Registry; Chinese Research Information Service 
Republic of Korea; Clinical Trials Registry India; Cuban 
Public Registry of Clinical Trials; German Clinical Trials 
Register; Iranian Registry of Clinical Trials; International 
Standard Randomised Controlled Trials Number Registry; 
Japan Primary Registries Network; Lebanese Clinical Trials 
Registry; Thai Clinical Trials Registry; The Netherlands 
National Trial Register; Pan African Clinical Trial Registry; 
Peruvian Clinical Trial Registry; and Sri Lanka Clinical Trials 
Registry. The following databases were searched: Embase, 
PubMed, and Web of Science. The search was last updated 
on March 17, 2020. Study coordinators were contacted for 
additional information if appropriate.
Eligible studies were identified and screened according to 
inclusion-exclusion criteria that were established a priori (Table 
1). Two authors independently screened the search results, 
and a third author resolved the disputes. Inter-rater agreement 
Inclusion Exclusion
1. Human study 1. (a) In vitro study or
    (b) In vivo study (e.g. animal model) or
    (c) Other non-human study (unless can be isolated)
2. Remdesivir (GS-5734) included 2. Remdesivir (GS-5734) not included in the article
3. (a) Case report or
    (b) Case series or
    (c) Letter of correspondence or
    (d) Observational study or
    (e) Clinical trial or
    (f) Randomized controlled trial
3. (a) Literature review or
    (b) Systematic review or
    (c) Meta-analysis or 
4. (a) Novel coronavirus or
    (b) 2019-nCov or
    (c) SARS-COV-2 or
    (d) COVID-19
4. (a) Other pathogen or virus included (e.g. Marburg)
Table 1. Inclusion-exclusion criteria for systematic review of studies regarding the use of remdesivir for treatment of COVID-19.
Studies that meet all the inclusion criteria may be included in the systematic review. Studies that meet any of the exclusion criteria 
should be excluded from the systematic review.
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was quantified by Cohen’s kappa scores as well as percentage 
agreement as recommended by McHugh.12 Studies were first 
screened by title and abstract and then by full-text review. Data 
were extracted by one author and included the following items: 
type of study; intervention; number of participants; patient 
outcomes; adverse events; and study characteristics. We used the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement as an aid in this report.13 There is 
no online review protocol for this study.
RESULTS
The database search yielded a total of 86 items from the 
following databases: Embase (n = 21), PubMed (n = 20), Web 
of Science (n = 28), European Union Clinical Trials Register (n 
= 2), and clinicaltrials.gov (n = 8). After removal of duplicates 
(n = 21), the first round of screening yielded eight potentially 
eligible items. Studies were excluded for meeting any of the 
following criteria: non-human study (n = 3); review or meta-
analysis (n = 15); not including SARS-CoV-2 (n = 16); or 
multiple criteria met (n = 23). Inter-rater agreement following 
the first round of screening was 98.5% (κ = 0.925). After the 
second round of screening, seven items were included. Inter-
rater agreement was 100%. Study characteristics are described 
in Table 2. 
This review of remdesivir identified ongoing and recruiting 
trials in 11 countries, including the United States, China, 
Taiwan, France, and Italy. The average number of participants 
was 450 (range = 308-600). Selection criteria for each trial 
varied according to the severity of symptoms (based on 
peripheral capillary oxygen saturation). Five trials involved a 
200-milligram (mg) intravenous (IV) loading dose following by 
maintenance dose of 100 mg for nine days. Two trials involved 
a single, 100-mg IV infusion. The primary outcomes for each 
trial were as follows: proportion of patients discharged (n = 
2); time to clinical improvement (n = 2); improved oxygen 
saturation (n = 2); normalization of body temperature (n = 2); 
and percentage of each severity rating on a 7-point ordinal scale 
to assess clinical status (n = 1). Secondary outcomes included 
adverse events (n = 7); length of stay (n = 2); mortality (n = 3); 
duration of ventilation or supplemental oxygen use (n = 3); and 
reduction in viral load (n = 2). Results are expected in April 
2020 (n = 2), May 2020 (n = 2), and April 2023 (n = 1). 
DISCUSSION
Our systematic search identified a total of 86 studies 
eligible for inclusion, of which seven were incorporated into 
a qualitative synthesis. All seven of the included studies were 
Phase 3 clinical trials that were either recruiting patients or 
considered ongoing. In each trial, IV remdesivir (100-200 
mg) was the primary intervention. The predominant treatment 
protocol described a 200 mg dose administered on the first day 
followed by subsequent doses of 100 mg each following day 
(for a total of 5 or 10 days depending on the treatment arm). 
However, none of the included studies have reported completed 
or partial data. As a result, the clinical utility of remdesivir for 
the treatment of COVID-19 remains to be seen, and any adverse 
events have yet to be reported. 
As early as 2017, Sheahan et al reported GS-5734 activity 
against MERS-CoV and SARS-CoV in human lung cells, 
suggesting that remdesivir may prove effective against endemic 
and emerging coronaviruses.14 Agostini et al later reported 
that GS-5734 effectively inhibited coronavirus replication in 
vivo despite intact exoribonuclease proofreading, indicating 
that remdesivir may have utility against resistant coronavirus 
strains.15 Further research has demonstrated the broad-spectrum 
activity of remdesivir for the purpose of treating endemic 
coronavirus infections.16
In December 2019, the first case of SARS-CoV-2 in the 
United States was successfully treated by IV remdesivir without 
adverse effects.11 The patient was treated with remdesivir 
on hospital day 7, and on day 8 the patient experienced 
symptomatic and clinical improvement significant enough to 
discontinue supplemental oxygenation with improved saturation 
in room air, as well as resolution of rales and anorexia. 
Remdesivir was first reported for treatment of EVD in 2016 
with subsequent studies indicating mixed results.10, 17-18 Ko et 
al argued that the findings from previous studies of remdesivir 
for EVD support testing of remdesivir for treatment of 
COVID-19.19 Concurrent in vitro research has supported the use 
of the drug to treat SARS-CoV-2 infections.20 In contrast, Zhang 
et al have raised concerns about the possibility of unknown 
adverse reactions.8
LIMITATIONS
The primary limitation of  this systematic review stems 
from the lack of reported patient outcomes from human trials, 
which are in varying phases of completion. Although some 
clinical trial registries display preliminary reports of ongoing 
trials, these partial data are  not available for quantitative 
analysis. Trials are scheduled to be completed as early as April-
May 2020.
CONCLUSION
There is both in vitro and limited clinical evidence that 
supports the use of remdesivir to treat SARS-CoV-2. However, 
Phase 3 clinical trials have not yet been completed and partial 
data has not yet been reported. The side-effects profile of 
remdesivir remains similarly not well defined. Until high-quality 
studies report significant improvements with administration 
of IV remdesivir, the use of this experimental drug should be 
limited to randomized controlled trials. Therefore, the potential of 
remdesivir as a standard of care therapy for COVID-19 remains 
to be determined.
NOTE: An addenum to this article has been written by the author 
AM.20
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ID
Trial 
Status Country
Number 
of Sites
Phase 
of Trial Intervention
Number of 
Participants
Primary 
Outcome(s)
NCT04292899 Recruiting Hong Kong
Republic of Korea
Singapore
United States
10 3 Intravenous RDV 200 mg on 
Day 1 followed by Intravenous 
RDV 100 mg for 4 days
Intravenous RDV 200 mg on 
Day 1 followed by Intravenous 
RDV 100 mg for 9 days
400 Improved 
oxygen 
saturation; 
Normalization 
of body 
temperature
NCT04292730 Recruiting Hong Kong
Republic of Korea
Singapore
United States
10 3 Intravenous RDV 200 mg on 
Day 1 followed by Intravenous 
RDV 100 mg for 4 days
Intravenous RDV 200 mg on 
Day 1 followed by Intravenous 
RDV 100 mg for 9 days
600 Proportion of 
discharged 
patients
NCT04257656 Recruiting China 1 3 Intravenous RDV 200 mg on 
Day 1 followed by Intravenous 
RDV 100 mg for 9 days
453 Time to clinical 
improvement 
(restricted to 28 
days)
NCT04252664 Recruiting China 1 3 Intravenous RDV 200 mg on 
Day 1 followed by Intravenous 
RDV 100 mg for 9 days
308 Time to clinical 
improvement 
(restricted to 28 
days)
NCT04280705 Recruiting Republic of Korea
Singapore
United States
20 3 Intravenous RDV 200 mg on 
Day 1 followed by Intravenous 
RDV 100 mg for 9 days
394 Percentage of 
each severity 
rating on 7-point 
ordinal scale 
with a 15 day 
time frame
2020-000841-15 Ongoing* China 
France 
Germany
Hong Kong
Italy
Japan
Republic of Korea
Singapore
Spain
Taiwan
United States
15 3 Intravenous RDV 100 mg 400 Improved 
oxygen 
saturation; 
Normalization 
of body 
temperature 
(restricted to 14 
days)
2020-000842-32 Ongoing* China 
France 
Germany
Hong Kong
Italy
Japan
Republic of Korea
Singapore
Spain
Taiwan
United States
15 3 Intravenous RDV 100 mg 600 Proportion of 
discharged 
participants 
(restricted to 14 
days)
Table 2. Study characteristics regarding the use of remdesivir for treatment of COVID-19.
*Trial status (as defined by ClinicalTrials.gov) regards a trial as ‘ongoing’ if it had one of these statuses: ‘Active, not recruiting’, ‘Available’, 
‘Enrolling by invitation’, ‘Not yet recruiting’, ‘Recruiting’, or ‘Suspended’.
RDV, Remdesivir; mg, milligrams.
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